74954-66-8Relevant academic research and scientific papers
1-(β-D-arabinofuranosyl)-5-propynyluracil for treatment of VZV infections
-
, (2008/06/13)
The invention is a method for using 1-(β-D-arabinofuranosyl)-5-propynyluracil or its salts as the active ingredient in pharmaceutical compositions in the treatment of varicella zoster viral infections whether expressed as chicken pox or shingles.
Acetylenic nucleosides. 4. 1-β-D-arabinofuranosyl-5-ethynylcytosine. Improved synthesis and evaluation of biochemical and antiviral properties
Bobek,Kavai,Sharma,Grill,Dutschman,Cheng
, p. 2154 - 2157 (2007/10/02)
5-Ethynyl-1-β-D-arabinofuranosylcytosine (EAC) was prepared from 1-(2,3,5-tri-O-acetyl-β-D-arabinofuranosyl)cytosine by iodination followed by coupling with (trimethylsilyl)acetylene and deblocking. At 50 μM, EAC was found to inhibit the in vitro replication of herpes simplex virus type 1 and type 2 by >99%. EAC also showed activity against a strain of HSV-1 resistant to (E)-5-(2-bromovinyl)-2'-deoxyuridine which has an alteration of the virus-induced thymidine kinase (TK).. At 100 μM, EAC did not inhibit the in vitro growth of leukemia L1210 and HeLa cells. EAC was resistant to the action of dCR-CR deaminase, its rate of deamination being approximately 2% that of dCR. The compound was a poor substitute for dCR kinase, but it was phosphorylated by HSV-1- and HSV-2-induced TKs at 50% and 30%, respectively, the rate of thymidine.
